1. Home
  2. BTBT vs CUVL Comparison

BTBT vs CUVL Comparison

Compare BTBT & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bit Digital Inc.

BTBT

Bit Digital Inc.

HOLD

Current Price

$1.70

Market Cap

427.6M

Sector

Finance

ML Signal

HOLD

Logo Clinuvel Pharmaceuticals Limited American Depositary Shares

CUVL

Clinuvel Pharmaceuticals Limited American Depositary Shares

N/A

Current Price

$6.14

Market Cap

374.2M

Sector

Miscellaneous

ML Signal

N/A

Company Overview

Basic Information
Metric
BTBT
CUVL
Founded
2015
N/A
Country
United States
Australia
Employees
N/A
16
Industry
Finance: Consumer Services
Miscellaneous
Sector
Finance
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
427.6M
374.2M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
BTBT
CUVL
Price
$1.70
$6.14
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
30.6M
17.6K
Earning Date
05-15-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$113,560,320.00
N/A
Revenue This Year
$38.96
N/A
Revenue Next Year
$89.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.10
N/A
52 Week Low
$1.18
$5.95
52 Week High
$4.55
$8.20

Technical Indicators

Market Signals
Indicator
BTBT
CUVL
Relative Strength Index (RSI) 60.32 38.85
Support Level $1.54 N/A
Resistance Level $1.74 $6.82
Average True Range (ATR) 0.14 0.45
MACD 0.02 -0.09
Stochastic Oscillator 91.09 2.67

Price Performance

Historical Comparison
BTBT
CUVL

About BTBT Bit Digital Inc.

Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.

About CUVL Clinuvel Pharmaceuticals Limited American Depositary Shares

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Share on Social Networks: